J&J Reminyl new Rxs top 10% share

Reminyl (galantamine) has "new Rx share hitting levels of over 10.4%" since its early May launch, J&J Worldwide Pharmaceuticals Chair Christine Poon tells Bear Stearns conference call Sept. 26. "The introduction of Reminyl has taken some of the steam off [Pfizer's/Eisai's] Aricept and [Novartis'] Exelon," Novartis Pharmaceuticals CEO Paulo Costa conceded during a separate Sept. 25 call. "Both products have been similarly impacted," Costa suggests, noting that Exelon's "new Rx market share is still fairly high at 21%"